Four major pharmacies reported first-quarter results, Dashenlin net profit increased by 50%

Four major pharmacies reported first-quarter results, Dashenlin net profit increased by 50%
Since the outbreak of the New Crown epidemic, offline retail pharmacies have responded to the government’s call to fully protect residents’ demand for drugs.In fact, hospitals have extended the prescription period and promoted the expansion of prescription outflows, which has benefited retail pharmacies, especially leading chain pharmacies.In the first quarter of this year, the average revenue and net profit of the four listed pharmacies Dashenlin, the common people, Yixintang and Yifeng pharmacies increased, and the total number of stores also increased to varying degrees.In the first quarter of this year, the revenue of the four chain pharmacies each exceeded 3 billion, respectively 33.6.2 billion, 32.8.2 billion, 30.8.7 billion and 30.48 ppm; net profit attributable to shareholders of listed companies is 2 respectively.8 billion yuan, 1.9.1 billion yuan, 1.9.6 billion and 2.05 billion.Dashenlin has the highest budget, with revenue and net profit more than doubled to 30.39% and 52.28%.Dashenlin is also the company with the largest number of mergers and acquisitions in the first quarter of the four pharmacies. It reported a merger, and the company initiated a total of 5 investment and merger businesses in the same industry.Among them, there were 3 M & A projects to be delivered in the previous year, 2 newly signed M & A projects, involving 166 stores; 1 equity investment project, the investment cost was 29.53 million yuan.In addition, the company also established a wholly-owned subsidiary “Jiangxi Dashenlin Pharmaceutical Technology Co., Ltd.” in Jiangxi to enhance the company’s brand influence and market competition in Jiangxi; the company’s wholly-owned subsidiary Ziyunxuan Chinese Medicine Technology Co., Ltd. was established in GuangxiThe wholly-owned subsidiary “Guangxi Kekekang Medical Devices Co., Ltd.” aims to consolidate the Guangxi market.As of the close of midday on April 29, Dashenlin has continued to grow by 16 this year.42%.Among the four major pharmacies, Yixintang has the largest number of stores, with a total of 6402 stores, an increase of 2 from the end of 2019.17%, including 84 medical insurance stores.54%.Yixintang said that in the first quarter of this year, the company focused on the development of Southwest and South China, while taking into account the development of stores in North China.As of the close of midday on April 29, Yixintang has continued to rise by 37 this year.4% is the highest growth among the four major chain pharmacies.Yifeng Pharmacy also completed a merger and acquisition business in the same industry in the first quarter of this year.In October 2019, Jiangsu Yifeng, a wholly-owned subsidiary of the company, and Ding Peisheng signed the “Xuzhou Enqi Pharmaceutical Chain Co., Ltd. Restructuring and Acquisition Framework Agreement” to acquire 65% of the equity of its newly established new company.Involving 31 stores, the project completed a 65% allocation change for the new company on March 31, 2020.The number of reports, the company’s total number of stores reached 4,869, the store size is 2.46%.As of midday closing on April 29, Yifeng Pharmacy has continued to rise by 29 this year.50%.The common people is the one with the largest number of new stores among the four chain pharmacies. Before and after the report, 356 new stores were added, including 208 new self-built stores, 34 mergers and acquisitions and 114 franchised stores in the scope of alternate consolidated statements; closed 21Stores, with a net increase of 335 stores.As of the end of the reporting period, there were 5,438 large pharmacy stores for ordinary people.As of the close of midday on April 29, the people have continued to expand this year.75%.Tianfeng Securities analysis pointed out that from the perspective of the industry, the “4 + 7” volume procurement policy will continue to be promoted in the future, and the terminal value of retail pharmacies may be further improved, and large chain pharmacies are expected to continue to exert their capital advantages andChain advantage leads the industry development.In the short term, in the first quarter of 2020, various retail pharmacies are important sales windows for anti-epidemic materials, anti-epidemic substances and anti-epidemic drugs, and related products have also achieved higher sales, which has a certain impact on the first quarter performance.During the epidemic, the four major pharmacies also made their own contributions.Such as Dashenlin, Yixintang’s non-operating expenses increased by 78% and 163.81% is due to donated medicines to the society.The data released in the quarterly report of the common people are more detailed. At the end of the monthly reporting period, the common people ‘s pharmacy donated protective clothing, goggles, and temperature measuring instruments to the Red Cross, epidemic control center in Hubei, Hunan, Gansu and other regions, Masks and other anti-epidemic materials worth 295.80 thousand yuan.Yifeng Pharmacy has not forgotten anything in the first quarter report, but according to various news reports, Yifeng Pharmacy lacks medical alcohol, protective clothing, masks and other epidemic prevention materials more than one million yuan.Editor Yue Qingxiu proofreading Chen Diyan

Zidao had a budget of nearly 400 million last year and was issued a qualified audit report

On April 30, Zhangzidao Group Co., Ltd. (hereinafter referred to as “Zhangzidao”) released the 2019 annual report and the first quarter report in 2020.In 2019, Zhangzi Island achieved revenue of 27.2.9 billion, down 2 every year.47%; realized net profit -3.9.2 billion, a decrease of 1321 per year.41%.The 2019 annual audit agency Asia Pacific (Group) Certified Public Accountants (Special General Partnership) issued a qualified opinion audit report for Zhangzidao and an internal control assurance report with negative opinions.In terms of products, in 2019, except sea cucumbers, sea urchins revenues exceeded ten years.39%, 39.Outside 7%, the revenues of scallops, abalones and conch were placed one after another.Zhangzidao said Conch’s revenue fell by 26.85% is due to the decrease in the number of days of harvesting operations compared to the previous one.And the scallops that have been repeatedly hit by disasters are still the main revenue source of Zhangzi Island, achieving revenue3.0.9 billion, down by 14.twenty two%.In response to the large quota in 2019, Zhangzidao said that the reason was due to the impact of large-scale death disasters, write-offs and impairments on bottom-seeded scallops.Among them, a total of write-off bottom-seeded scallops 43.570,000 mu, write-off costs 2.US $ 3.1 billion; total inventory depreciation reserve is ready to be used for bottom-seeding scallops12.480,000 mu, the provision amount of inventory falling price reserve is 6,055.440,000 yuan.On the same day, Zhangzidao released its first quarter report for 2020. In the first quarter, Zhangzidao achieved operating income3.9.8 billion, down 28 a year.68%; realized net profit of 371.390,000 yuan, an increase of 108 per year.61%; non-net profit deduction is -7136.360,000 yuan, down 57 every year.77%.In essence, regarding the above two financial reports, Zhang Zidao’s director Luo Weixin and supervisor Zou Dezhi both stated that the financial report was provided late and the amount of information was large, which could not guarantee the truthfulness, accuracy and completeness of the relevant operating information.Among them, for the 2019 annual report, Luo Weixin voted against it; as the 2019 annual audit agency, Asia Pacific (Group) Accounting Firm (Special General Partnership) issued a qualified opinion audit report for Zhangzidao, and issued a negative opinion of internal control assurancereport.Sauna, Ye Wang Wang Siyang editor Li Yan proofreads Wei Zhuo